Cencora, Inc. $COR Shares Sold by Staley Capital Advisers Inc.

Staley Capital Advisers Inc. trimmed its holdings in Cencora, Inc. (NYSE:COR) by 25.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 6,087 shares of the company’s stock after selling 2,100 shares during the period. Staley Capital Advisers Inc.’s holdings in Cencora were worth $2,056,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in COR. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $26,000. Archer Investment Corp boosted its holdings in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC bought a new stake in Cencora in the third quarter worth $30,000. Cloud Capital Management LLC bought a new stake in Cencora in the third quarter worth $31,000. Finally, Caitlin John LLC bought a new position in Cencora in the third quarter worth $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of a number of analyst reports. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Citigroup dropped their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Morgan Stanley set a $342.00 target price on Cencora in a research note on Friday, May 8th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research note on Monday, May 4th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Stock Down 1.6%

NYSE COR opened at $256.96 on Friday. The stock has a market capitalization of $49.99 billion, a PE ratio of 19.71, a PEG ratio of 1.19 and a beta of 0.64. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The business has a fifty day moving average price of $314.65 and a two-hundred day moving average price of $339.22. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts expect that Cencora, Inc. will post 17.76 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.